Rubbing my ball, page-585

I pinched some info from over at RAC. Its really important to understand how big the pharma market is and how much they are willing to pay.
Below are a list of buyout figures.

Immunomedics 2020 USD $21.00B FDA Approval Antibody-Drug Conjugates (ADCs)
Pharmacyclics 2015 USD $21.00B FDA Approval BTK Inhibitor
Array BioPharna 2019 USD $11.40B FDA Approval BRAF/MEK Inhibitors
Medivation 2016 USD $14.00B Various Androgen receptor inhibitor, PARP inhibitor
Loxo Oncology 2019 USD $8.00B FDA Approval TRK Inhibitor
Juno Therapeutics 2018 USD $9.00B Phase I & II CAR-T
Kite Pharma 2017 USD $11.90B FDA Approval CAR-T
Forty Seven USD $4.9B

IMU has 4.7B SOI

@ Forty Seven figure works out at $1ps
@ average of list above $12.6 B works out at $2.68ps
@ Immunomedics figure works out at $4.47ps
(figures are in US dollars)

As you can see above its pretty lofty stuff.
On the share price, 12 months ago the IMU sp was 2c so at 10c its fair to say its been a good year. The problem we have now is our MC is nearing $500M and IMO we need some seriously derisking announcements to push the SP up to 20C or $1B MC. Unfortunately with 4.7B SOI the sp won't be going on a RAC like charge unless partnership/buyout talk starts.
Our trials are progressing well, our management are happy with what they are seeing and importantly their are no side effects. It all just takes time - who knows if its one year, 2 years, 4 years??
For me, IMU isn't a stock that will slowly grow to a dollar because that would be a $5B MC. Its more like a fire cracker. Light it, wait, wait, wait BOOM.

I pinched Wombat777's research above. He deserves all the credit for it. Don't take it all to seriously, its just an attempt to show the size of pharma.